Market News AIOpen the app

Scinai's CEO tells shareholders about growth in its CDMO business and more time to operate.

DealRead the original at prnewswire.com
Good for SCNI

Scinai's committed customer orders climbed, and its reported cash runway now reaches late 2027. This supports growth, but extra contract phases are possible rather than secured.

SCNI · Scinai Immunotherapeutics

AI read · Good for SCNI

The AI's read

More confirmed customer work gives Scinai a stronger base for its manufacturing business. The cash also gives it time to pursue that work. The main limit is that extra project phases are not promised. Scinai also says it is focused on building a profitable CDMO business, so this update does not show that goal has been reached.

Get alerts for SCNI

Follow Scinai Immunotherapeutics (SCNI) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for SCNI
Free on the App Store and Google Play, or on the web.